Atypical hemolytic uremic syndrome research hub
4 indexed studies · 4 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy
This study is looking at a new medicine called IPTACOPAN for adults who have a rare kidney disease called atypical hemolytic uremic syndrome (aHUS). It wants to see if the medicine helps improve blood and kidney problems without needing other common treatments.
Slovenia · Slovakia · Czechia - recruiting
National Registry of Rare Kidney Diseases
This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.
United Kingdom - recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
This study is gathering important information about a rare kidney disease called atypical Hemolytic-Uremic Syndrome (aHUS). It looks at how the disease progresses and how safe new treatments like eculizumab and ravulizumab are for patients of all ages.
United States · Australia · Belgium - recruitingPHASE3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
This study looks at switching from current aHUS treatment (anti-C5 antibodies) to a new treatment called iptacopan. Researchers want to see if iptacopan is safe and effective for adults with aHUS who are already doing well on their current medication.
China · France · Germany